45.17
0.32 (0.71%)
| Previous Close | 44.85 |
| Open | 44.92 |
| Volume | 226,822 |
| Avg. Volume (3M) | 472,421 |
| Market Cap | 1,427,867,776 |
| Price / Earnings (TTM) | 27.71 |
| Price / Earnings (Forward) | 4.95 |
| Price / Sales | 1.90 |
| Price / Book | 3.92 |
| 52 Weeks Range | |
| Earnings Date | 26 Feb 2026 |
| Profit Margin | 6.61% |
| Operating Margin (TTM) | 13.71% |
| Diluted EPS (TTM) | 1.22 |
| Quarterly Revenue Growth (YOY) | 22.70% |
| Quarterly Earnings Growth (YOY) | -91.30% |
| Total Debt/Equity (MRQ) | 411.94% |
| Current Ratio (MRQ) | 1.08 |
| Operating Cash Flow (TTM) | 198.44 M |
| Levered Free Cash Flow (TTM) | 341.32 M |
| Return on Assets (TTM) | 7.95% |
| Return on Equity (TTM) | 19.23% |
Market Trend
| Short Term | Medium Term | ||
| Industry | Drug Manufacturers - Specialty & Generic (US) | Mixed | Mixed |
| Drug Manufacturers - Specialty & Generic (Global) | Mixed | Mixed | |
| Stock | Collegium Pharmaceutical, Inc. | Bullish | Bullish |
AIStockmoo Score
| Analyst Consensus | 4.0 |
| Insider Activity | -3.0 |
| Price Volatility | -0.5 |
| Technical Moving Averages | 0.0 |
| Technical Oscillators | -0.5 |
| Average | 0.00 |
|
Collegium Pharmaceutical Inc is a specialty pharmaceutical company. The company is engaged in developing and planning to commercialize abuse-deterrent products that incorporate its patented DETERx platform technology for the treatment of chronic pain and other diseases. The DETERx platform technology is designed to maintain the extended-release and safety profiles of highly abused drugs in the face of various methods including chewing, crushing, and dissolving. Its product portfolio includes Xtampza ER, which is an abuse-deterrent, extended-release, oral formulation of oxycodone; and Nucynta Products, which are extended-release and immediate-release formulations of tapentadol; Belbuca, and Symproic. |
|
| Sector | Healthcare |
| Industry | Drug Manufacturers - Specialty & Generic |
| Investment Style | Small Value |
| % Held by Insiders | 1.69% |
| % Held by Institutions | 117.12% |
| 52 Weeks Range | ||
| Price Target Range | ||
| High | 60.00 (HC Wainwright & Co., 32.83%) | Buy |
| Median | 56.00 (23.98%) | |
| Low | 54.00 (Needham, 19.55%) | Buy |
| Average | 56.67 (25.46%) | |
| Total | 3 Buy | |
| Avg. Price @ Call | 45.10 | |
| Firm | Date | Target Price | Call | Price @ Call |
|---|---|---|---|---|
| Needham | 26 Feb 2026 | 54.00 (19.55%) | Buy | 44.22 |
| 08 Jan 2026 | 56.00 (23.98%) | Buy | 48.78 | |
| Barclays | 09 Jan 2026 | 56.00 (23.98%) | Buy | 45.54 |
| HC Wainwright & Co. | 09 Jan 2026 | 60.00 (32.83%) | Buy | 45.54 |
| Name | Avg. Buy ($) | Avg. Sell ($) | Net Quantity | Net Value ($) |
|---|---|---|---|---|
| DREYER SCOTT | - | 39.99 | -49,976 | -1,998,540 |
| Aggregate Net Quantity | -49,976 | |||
| Aggregate Net Value ($) | -1,998,540 | |||
| Aggregate Avg. Buy ($) | - | |||
| Aggregate Avg. Sell ($) | 39.99 | |||
| Name | Holder | Date | Type | Quantity | Price | Value ($) |
|---|---|---|---|---|---|---|
| DREYER SCOTT | Officer | 03 Mar 2026 | Automatic sell (-) | 49,976 | 39.99 | 1,998,540 |
| Date | Type | Details |
|---|---|---|
| 15 Jan 2026 | Announcement | Collegium to Present Four Real-World Data Posters at APSARD 2026 Annual Conference |
| 08 Jan 2026 | Announcement | Collegium Provides 2026 Financial Guidance and Business Update |
| 30 Dec 2025 | Announcement | Collegium Announces the Closing of $980 Million Syndicated Credit Facility |
The support, resistance and trendline levels presented has been generated by an artificial intelligence (AI) model and should be interpreted with caution.
Portfolio
| Realized Profit | - |
| Unrealized Profit | - |
| Dividend Received 2026 | - |
| Total Profit | - |
| Avg. Return | - |
| Quantity (Buy) | - |
| Avg. Price (Buy) | - |
| Quantity (Sold) | - |
| Avg. Price (Sold) | - |